Floatz logo

Anti-Cd70-Car-T Cells

Cutaneous T-cell Lymphoma (CTCL)

Tianjin Medical University Cancer Institute and HospitalCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Cutaneous T-cell Lymphoma (CTCL) cohort.

Asset / SponsorPhaseRating
Brentuximab Vedotin
Assistance Publique - Hôpitaux de Paris
Phase 3BB
A-DMDT390-BISFV(UCHT1)
Virogen Biotechnology Inc.
Phase 2CCC
PURINOSTAT
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2CCC
Rapamycin
Stefan Schieke MD
Phase 2CCC
Selinexor
Karyopharm Therapeutics Inc
Phase 2CCC

View all 10 →

Same molecule, other indications

Anti-Cd70-Car-T Cells is also rated in:

Metastatic TumorDormant
CC
Indicative ·
43 / 100
View asset →
Relapsed / Refractory Solid TumorDormant
CC
Indicative ·
43 / 100
View asset →
Cervix CancerDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →